Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elfabrio (pegunigalsidase alfa-iwxj) is a PEGylated enzyme replacement therapy (ERT) for the treatment of adult patients with Fabry disease. It is a recombinant human α–Galactosidase–A enzyme expressed in plant-cell culture that is designed to provi...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
October 05, 2023
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX-102 (pegunigalsidase alfa), EC authorized, is a novel PEGylated, covalently crosslinked form of α-galactosidase-A developed as enzyme replacement therapy for fabry disease, was designed to increase plasma half-life and reduce immunogenicity, thereby...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
May 05, 2023
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRX-115
Therapeutic Area : Rheumatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX-115 is a PEGylated enzyme expressed via ProCellEx® for intravenous (IV) administration of recombinant Uricase, designed for safe and efficacious treatment of refractory gout
Product Name : PRX-115
Product Type : Enzyme
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : PRX-115
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme. It is a novel, PEGylated ERT under development for the treatment of Fabry d...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegunigalsidase alfa (PRX–102) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme. Protein sub-units are covalently bound via chemical cross-linking using sho...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following the switch to pegunigalsidase alfa there was a decrease in patients with progressing or fast progressing kidney disease, and the majority of patients achieved a stable status post-switch.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 is currently being studied in the pivotal Phase III BALANCE clinical trial and in two ongoing long-term extension studies, all of which are part of the overall clinical development of PRX–102 for the proposed treatment of Fabry disease.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
February 06, 2021
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Psagot Investment House
Deal Size : $43.7 million
Deal Type : Financing
Protalix BioTherapeutics Announces $43.7 Million in Financing
Details : Financing will advance the Company's clinical programs and commercialization of PRX-102 for the treatment of Fabry disease, as well as to further develop its early stage pipeline of therapeutics.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Undisclosed
December 03, 2020
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Psagot Investment House
Deal Size : $43.7 million
Deal Type : Financing
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
November 08, 2020
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable